As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications. On May 18, 2021, Québec announced that, subject to exceptions, patients who use a reference biologic for which one or more biosimilars are available will have to switch, under the supervision of their doctor, to a biosimilar drug by April 12, 2022. According to the announcement, this shift will result in annual savings of over $100 million dollars. Québec’s website on biosimilar drugs includes a section on the current situation regarding reimbursement.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
CDA opens consultation on proposed list of drugs to inform development of national formulary
On June 19, 2025, Canada’s Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.Read More -
Finalized PMPRB Guidelines published
On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.Read More